Drug discovery in ovarian cancer

Recent Patents on Anti-Cancer Drug Discovery

Volumn 5, Issue 3, 2010, Pages 251-260

  Chase, Dana M ^a   Mathur, Nidhee ^a   Tewari, Krishnansu S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Chemotherapy; Clinical trials; Ovarian cancer; Recurrent cancer; Targeted therapy

Indexed keywords

AFLIBERCEPT; AMG 386; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIBF 1120; CANCER VACCINE; CANFOSFAMIDE; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; EC 145; EVEROLIMUS; GDC 0449; IMC 112B; IMC 3G3; MONOCLONAL ANTIBODY; OLAPARIB; PACLITAXEL; PAZOPANIB; PLACEBO; PLATINUM AMMINE CYCLOHEXYLAMINE DICHLORIDE; PV 701; RAMUCIRUMAB; SATRAPLATIN; TOPOTECAN; TRABECTIDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VOLOCIXIMAB; ENDOTHELIAL CELL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; FATIGUE; GASTROINTESTINAL SYMPTOM; GYNECOLOGIC CANCER; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; INTESTINE PERFORATION; KIDNEY CARCINOMA; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; MYALGIA; NANOTECHNOLOGY; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PAIN; PERITONEUM CANCER; PRIORITY JOURNAL; RESPIRATORY ARREST; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; DRUG ANTAGONISM; DRUG DEVELOPMENT; FEMALE; METABOLISM; OVARY TUMOR; REVIEW;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DRUG DISCOVERY; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; OVARIAN NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 78349249813     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489210791760472     Document Type: Article

References (70)

1. Li JL, Harris AL. Crosstalk of and in tumour: Therapeutic implications. Front Biosci 2009; 14: 3094-3110.
2. Fyfe, G., Holmgren, F., Mass, R.D., Novotny, W. Treatment with anti-VEGF antibodies. US7622115 (2009).
3. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2007; 25(33): 5165-71.
4. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25(33): 5180-6. Erratum in: J Clin Oncol 2008; 26(10): 1773.
5. Ma WW, Jimeno A. Strategies for suppressing angiogenesis in gynecologic cancers. Drugs Today (Barc) 2007; 43(4): 259-73.
6. Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann J, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003; 9: 5721-28.
7. Berdel, W.E., Mesters, R.M. Fusion polypeptides, and use thereof in antivascular tumor therapy. US76189434 (2005).
8. Colombo N, Mangili G, Mammoliti S, Kalling M, Tholander B, Sternas L, et al. Aflibercept (VEGF Trap) for advanced epithelial ovarian cancer (EOC) patients (pts) with symptomatic malignant ascites: Preliminary results of a pilot study. J Clin Oncol 2008; 26: (May 20 suppl; abstr 14598). 2008 ASCO Annual Meeting.
9. Tew WP, Colombo I, Ray-Coquard A, del Campo J, Scambia G, Springgs D. VEGF-Trap for patients with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study. J Clin Oncol 2007; 25(18S): 5508.
10. Huth, A., Zorn, L., Krueger, M., Ince, S., Thierauch, K.H., Menrad, A., Haberey, M., Hess-Stumpp, H. VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines. US7517894 (2009).
11. Camidge DR, Eckhardt SG, Diab S, Gore L, Chow L, O'Bryant C, et al. A phase I dose-escalation study of weekly IMC-1121B, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer. J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I. vol. 24, no. 18S (June 20 Suppl), 2006: 3032.
12. http://clinicaltrials.gov/ct2/show/NCT00479817 (Accessed on: June 18, 2010).
13. Zhang L, Yang N, Park JW, Katsaros D, Fracchioli S, Cao G. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 2003; 63(12): 3403-12.
14. Hata K, Nakayama K, Fujiwaki R, Katabuchi H, Okamura H, Miyazaki K. Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer. Gynecol Oncol 2004; 93(1): 215-22.
15. Daly, T.J., Fandl, J.P., Papadopoulos, N.J. VEGF-binding fusion proteins. US7635474 (2009).
16. Herbst R, Hong D, Chap L, Kurzrock R, Jackson E, Silverman J, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009; 27(21): 3557-65.
17. Ostman A, Heldin CH. Involvement of platelet-derived growth factor in disease: Development of specific antagonists. Adv Cancer Res 2001; 80: 1-38.
18. Guan, H., Liang, C., Sun, L., Tang, P.C., Wei, C.C., Vojkovsky, T., Qingwu, J., Herrinton, P.M., Mauragis, M.Al. 3-(4-amidopyrrol-2- ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors. US7582756 (2009).
19. Henriksen R, Funa K, Wilander E, Backstrom T, Ridderheim M, Oberg K. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 1993; 53: 4550-4.
20. Youssoufian, Amato RJ, Sweeney CJ, Chiorean EG, Fox F, Katz T, et al. Phase 1 study of IMC-3G3, an IgG1 monoclonal antibody targeting PDGFR in patients with advanced solid malignancies. J Clin Oncol (Meeting Abstracts) 2008 26: 14617.
21. Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009; 15(12): 4220-7.
22. Ramakrishnan, V., Bhaskar, V., Ho, S., Murray, R., Law, D. Use of anti-.alpha.5.beta.1 antibodies to inhibit cancer cell proliferation. US7662384 (2010).
23. Ramakrishnan V, Bhaskar V, Law DA, Wong MH, DuBridge RB, Breinberg D, et al. Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol 2006; 5(4): 273-86.
24. Bhaskar V, Zhang D, Fox M, Seto P, Wong MH, Wales PE, et al. A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo. J Transl Med 2007; 5: 61.
25. Bruncko, M., Ding, H., Elmore, S.W., Kunzer, A.R., Lynch, C.L., McClellan, W.J., Park, C.M., Song, X., Wang, Xl. Apoptosis promoters. US7390799 (2008).
26. Ricart AD, Tolcher AW, Liu G, Holen K, Schwartz G, Albertini M, et al. Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: A phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res 2008; 14(23): 7924-9.
27. Yazji S, Bukowski R, Kondagunta V, Figlin R. Final results from phase II study of volociximab, an 5 1 anti-integrin antibody, In refractory or relapsed metastatic clear cell renal cell carcinoma (mCCRCC). J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. vol. 25, no. 18S (June 20 Suppl), 2007: 5094.
28. Vergote IB, Colombo N, Kutarska E, Del Campo J, Pippitt C, Casado A, et al. Phase II study comparing volociximab (an antiangiogenic antibody) and pegylated liposomal doxorubicin (PLD) with PLD alone in recurrent ovarian or primary peritoneal cancer. J Clin Oncol 2009; ASCO Annual Meeting Proceedings (Post-meeting Edition) 27(15S): 5560.
29. Bradshaw, C.W., Doppalapudi, V.R., Lai, J.Y., Rizzo, J. Anti- angiogenic compounds. US7521425 (2009).
30. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, et al. BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockage and good antitumor efficacy. Cancer Res 2008; 68(12): 4774-82.
31. du Bois A, Huober J, Stopfer P, Pfisterer J, Wimberger P, Loibl S, et al. A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. Ann Oncol 2010; 21(2): 370-5.
32. Beaton, G., Moree, W.J., Rueter, J.K., Dahl, R.S., McElligott, D.L., Goldman, P., Demaggio, A.J., Christenson, E., Herendeen, D., Fowler, K.W., Huang, D., Bertino, J.E., Bourdon, L.H., Fairfax, D.J., Jiang, Q., Reisch, H.A., Song, R.H., Zhichkin, P.E. PARP inhibitors. US6924284 (2005).
33. http://clinicaltrials.gov/ct2/show/NCT00516373?term=PARP&rank =1 (Accessed on: June 18, 2010).
34. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361(2): 123-34.
35. Audeh MW, Penson RT, Friedlander B, Powell B, Bell-McGuinn KM, Scott C, et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J Clin Oncol 2009; 27: 15s, (suppl; abstr 5500).
36. Hummersone, M.G., Gomez, S., Menear, K.A., Cockcroft, Z.L.F., Smith, G.C.M. mTOR inhibitor compounds. US7504397 (2009).
37. Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, Hayashi M, et al. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res 2009; 15(17): 5404-13.
38. Campone M, Levy V, Bourbouloux E, Rigaud BD, Bootle D, Dutreix C, et al. Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. Br J Cancer 2009; 100(2): 315-21.
39. Beachy, P.A., Chen, J.K., Taipale, A.J.N. Modulators of hedgehog signaling pathways, compositions and uses related thereto. US7655674 (2010).
40. Bhattacharya R, Kwon J, Ali B, Wang E, Patra S, Shridhar V, et al. Role of hedgehog signaling in ovarian cancer. Clin Cancer Res 2008; 14(23): 7659-66.
41. Vlahov, I.R., Leamon, C.P., Parker, M.A., Howard, S.J., Santhapuram, H.K., Satyam, A., Reddy, J.A. Vitamin receptor binding drug delivery conjugates. US7601332 (2009).
42. Leaman CP, Reddy JA, Wlahov IR, Westrick E, Parker N, Nicoson JS, et al. Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145. Int J Cancer 2007; 121:1585-92.
43. Reddy JA, Dorton R, Westrick E, Dawson A, Smith T, Xu L, et al. Preclinical evaluation of EC145, a Folate-Vinca alkaloid conjugate. Cancer Res 2007; 67(9): 4434-42.
44. Li J, Sausville EA, Klein PJ, Morgenstern D, Leamon CP, Messmann RA, et al. Clinical pharmacokinetics and exposure- toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients. J Clin Pharmacol 2009; 49(12): 1467-76.
45. Manzanares, I., Martin, M.J., Rodriguez, A., Munt, S., Cuevas, C., Perez, M. Antitumoral analogs of ET-743. US7410969 (2008).
46. Duan Z, Choy E, Harmon D, Yang C, Ryu K, Schwab J, et al. ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines. PLoS One 2009; 4(9): e6967.
47. Del Campo JM, Roszak A, Bidzinski M, Ciuleanu TE, Hogberg T, Wojtukiewicz MZ, et al. Yondelis Ovarian Cancer Group. Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol 2009; 20(11): 1794-802.
48. rd ESMO Congress, Stockholm, Sweden 2008.
49. Matteucci, M., Rao, P., Duan, J.X. Compositions and methods for treating cancer. US7550496 (2009).
50. Vergote I, Finkler N, del Campo J, Lohr A, Hunter J, Matei D, et al. Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur J Cancer 2009; 45(13): 2324-32.
51. Sohn, Y.S., Lee, S.S., Lee, Y.A., Kim, K.M., Lee, C.O. Anticancer (IV) complexes for oral administration and a method of making the same. US5998648 (1999).
52. Kelland LL. Broadening the clinical use of platinum drug-based chemotherapy with new analogues: Satraplatin and picoplatin. Expert Opin Investig Drugs 2007; 16(7): 1009-21.
53. Wosikowski K, Lamphere L, Unteregger G, Jung V, Kaplan F, Xu JP, et al. Preclinical antitumor activity of the oral platinum analog satraplatin. Cancer Chemother Parmacol 2007; 60: 589-600.
54. Roberts, M.S., Lorence, R.M., Groene, W.S., Rabin, H., von Borstel, R.W. Treatment of neoplasms with viruses. US7470426 (2008).
55. http://www.cancer.gov/cancertopics/pdq/cam/NDV/HealthProfessional/ (Accessed on: April 4, 2010).
56. Cassel WA, Garrett RE. Newcastle disease virus as a n antineoplatic agent. Cancer 1965; 4: 863-8.
57. Lorence RM, Roberts MS, O'Neil JD, Groene WS, Miller JA, Mueller SN, et al. Phase 1 clinical experiences using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr Cancer Drug Targets 2007; 7: 157-67.
58. + T-cells. US7632506 (2009).
59. Chen YT, Hsu M, Lee P, Shin SJ, Mhawech-Fauceglia P, Odunsi K, et al. Cancer/testis antigen CT45: Analysis of mRNA and protein expression in human cancer. Int J Cancer 2009; 124(12): 2893-8.
60. Diefenbach CS, Gnjatic S, Sabbatini P, Aghajanian C, Hensley ML, Spriggs DR, et al. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res 2008; 14(9): 2740-8.
61. Gabrin, M., Brower, S., McDonald, S., Gallion, H., Nanavati, P., Rice, S.D., Chattopadhyay, A. Chemo-sensitivity assays using tumor cells exhibiting phenotypic characteristics. US7642048 (2010).
62. Gallion H, Christopherson WA, Coleman RL, Demars L, Herzog T, Hosford S, et al. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer 2006; 16: 194-201.
63. Curran, D.P., Josien, H., David, B. Camptothecin analogs and methods of preparation thereof. US7655640 (2010).
64. Schluep T, Hwang J, Cheng J, Heidel JD, Bartlett DW, Hollister B, et al. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res 2006; 12(5): 1606-14.
65. Numbenjapon T, Wang J, Colcher D, Schluep T, Davis ME, Duringer J, et al. Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models. Clin Cancer Res 2009; 15(13): 4365-73.
66. Gerrits CJ, Burris H, Schellens JH, Eckardt JR, Planting AS, van der Burg ME, et al. Oral topotecan given once or twice daily for ten days: Aphase I pharmacology study in adult patients with solid tumors. Clin Cancer Res 1998; 4(5): 1153-8.
67. Tallant, E.A., Gallagher, P.E., Ferrario, C.M. Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth. US7375073 (2008).
68. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998; 352(9123): 179-84.
69. Ino K, Shibata K, Kajiyama H, Nawa A, Nomura S, Kikkawa F. Manipulating the angiotensin system--new approaches to the treatment of solid tumours. Expert Opin Biol Ther 2006; 6(3): 243-55.
70. Suganuma T, Ino K, Shibata K, Kajiyama H, Nagasaka T, Mizutani S, et al. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res 2005; 11(7): 2686-94.